Health consequences of weight stigma: implications for obesity prevention and treatment
To prevent challenges with dosing errors and overdoses, the FDA encourages people to talk with their healthcare provider to clarify how to measure and administer correct doses with a syringe
WB, IHC-F, IHC-P, ICC/IF Blue ice -20C 12 months Please avoid freeze-thaw cycles.
Unlike vials and syringes, the pen requires no reconstitution or drawing up
Despite their success, access to incretin peptide analogues is challenging for most individuals that require these therapies due to their high cost and complex manufacturing process leading to supply shortages, as well as requirement for refrigeration and administration by injection, together with notable side effects including gastrointestinal disturbances, prompting further research into the development of a new wave of small molecules (8, 9), including those targeting the receptor as allosteric or ago-allosteric modulators (10, 11)
Medicare pricing $245/month (government price) $50/month copay for beneficiaries Eligibility: BMI 27 + metabolic risk factor (prediabetes, HTN, etc.) BMI 30 + CKD, HF, uncontrolled BP BMI 35 regardless of comorbidities Medicaid Will also receive reduced pricing Rollout depends on state decision timelines This expands coverage to millions of Americans